(2026). Prognostic Value of Next‐Generation Flow Cytometry Versus Dual‐Tracer PET/CT for Minimal Residual Disease Assessment in Multiple Myeloma. Cancer Medicine.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Prognostic Value of Next‐Generation Flow Cytometry Versus Dual‐Tracer PET/CT for Minimal Residual Disease Assessment in Multiple Myeloma."
Cancer Medicine 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Prognostic Value of Next‐Generation Flow Cytometry Versus Dual‐Tracer PET/CT for Minimal Residual Disease Assessment in Multiple Myeloma."
Cancer Medicine, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.